Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab

Journal of Infectious Diseases

Volumn 203, Issue 5, 2011, Pages 674-682

  Zhu, Qing ^a   McAuliffe, Josie M ^a   Patel, Nita K ^a   Palmer Hill, Frances J ^a   Yang, Chin Fen ^a   Liang, Brandon ^a   Su, Lan ^a   Zhu, Wei ^a   Wachter, Leslie ^a   Wilson, Susan ^a   MacGill, Randall S ^a   Krishnan, Subramaniam ^a   McCarthy, Michael P ^a   Losonsky, Genevieve A ^a   Suzich, JoAnn A ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; GLUTAMIC ACID; GLUTAMINE; HYBRID PROTEIN; LYSINE; METHIONINE; MOTAVIZUMAB; PALIVIZUMAB; THREONINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; IMMUNOPROPHYLAXIS; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS ISOLATION; VIRUS MUTANT; VIRUS NEUTRALIZATION; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFANT; MOLECULAR SEQUENCE DATA; MUTATION; NASAL MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79751502456     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq100     Document Type: Article

References (43)

1. Collins PL, McIntosh K, Channock RM. Respiratory syncytial virus. Fields virology, 3rd ed. Philadelphia, PA: Lippincott-Raven, 1996; 1313-96.
2. Johnson PR Jr, Olmsted RA, Prince GA, et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 1987; 61:3163-6.
3. Brandt CD, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 1973; 98:355-64.
4. Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288:498-505.
5. Hall CB. Respiratory syncytial virus. Textbook of pediatric infectious diseases, 4th ed. Philadelphia, PA: WB Saunders, 1998; 2084-110.
6. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82:199-203.
7. Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329:1524-30. (Pubitemid 23332437)
8. Hall CB, Kopelman AE, Douglas RG Jr, Geiman JM, Meagher MP. Neonatal respiratory syncytial virus infection. N Engl J Med 1979; 300:393-6. (Pubitemid 9134284)
9. Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990; 161:402-6.
10. Law BJ, De Carvalho V. Respiratory syncytial virus infections in hospitalized Canadian children: regional differences in patient populations and management practices. The Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1993; 12:659-63. (Pubitemid 23231162)
11. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307:397-400. (Pubitemid 12089293)
12. Raes M, Peeters V, Alliet P, et al. Peripheral blood T and B lymphocyte subpopulations in infants with acute respiratory syncytial virus brochiolitis. Pediatr Allergy Immunol 1997; 8:97-102. (Pubitemid 27483085)
13. Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999; 103:619-26. (Pubitemid 29274510)
14. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161:1501-7. (Pubitemid 30329018)
15. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40. (Pubitemid 37352516)
16. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.The IMpact-RSV Study Group. Pediatrics 1998; 102:531-7.
17. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-24. (Pubitemid 27460986)
18. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368:652-65. (Pubitemid 46527610)
19. Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005; 350:126-44. (Pubitemid 40804737)
20. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989; 63:2941-50. (Pubitemid 19156013)
21. Zhao X, Chen FP, Megaw AG, Sullender WM. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 2004; 190:1941-6. (Pubitemid 39564699)
22. Zhao X, Chen FP, Sullender WM. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004; 318:608-12. (Pubitemid 38224303)
23. Zhao X, Liu E, Chen FP, Sullender WM. In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J Virol 2006; 80:11651-7.
24. DeVincenzo JP, Hall CB, Kimberlin DW, et al. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)- resistant mutants. J Infect Dis 2004; 190:975-8. (Pubitemid 39120976)
25. Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol 2008; 42:52-7.
26. Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125:e35-51.
27. Buchholz UJ, Finke S, Conzelmann KK. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 1999; 73:251-9. (Pubitemid 28565367)
28. Jin H, Clarke D, Zhou HZ, et al. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. Virology 1998; 251:206-14. (Pubitemid 28527732)
29. Lennette EH, Schmidt NJ. Diagnostic procedures for viral, rickettsial and chlamydial infections, 5th ed. Washington, DC: American Public Health Association Publications, 1979.
30. Zhao X, Sullender WM. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 2005; 79:3962-8.
31. Domingo E, Holland JJ. Mutation rates and rapid evolution of RNA viruses. In Morse SS, ed. The evolutionary biology of viruses. New York, NY: Raven Press, 1994; 161-84.
32. Crowe JE Jr, Gilmour PS, Murphy BR, et al. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis 1998; 177:1073-6. (Pubitemid 28155165)
33. Garcia-Barreno B, Portela A, Delgado T, Lopez JA, Melero JA. Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J 1990; 9:4181-7.
34. Lopez JA, Penas C, Garcia-Barreno B, Melero JA, Portela A. Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus. J Virol 1990; 64:927-30. (Pubitemid 20032714)
35. Sullender WM, Edwards KG. Mutations of respiratory syncytial virus attachment glycoprotein G associated with resistance to neutralization by primate polyclonal antibodies. Virology 1999; 264:230-6. (Pubitemid 29531905)
36. Walsh EE, Falsey AR, Sullender WM. Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J Gen Virol 1998; 79(Pt 3);479-87.
37. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-9. (Pubitemid 20264145)
38. Nara PL, Smit L, Dunlop N, et al. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol 1990; 64:3779-91. (Pubitemid 20227202)
39. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254-63.
40. Groothuis JR, Nishida H. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr Int 2002; 44:235-41. (Pubitemid 34827718)
41. McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 2010; 17:248-50.
42. Carsillo T, Zhang X, Vasconcelos D, Niewiesk S, Oglesbee M. A single codon in the nucleocapsid protein C terminus contributes to in vitro and in vivo fitness of Edmonston measles virus. J Virol 2006; 80:2904-12. (Pubitemid 43346385)
43. Novella IS, Ball LA, Wertz GW. Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J Virol 2004; 78:9837-41. (Pubitemid 39187103)